A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination with Pembrolizumab in Patients with Select Advanced Cancers
A study of repotrectinib versus crizotinib in participants with locally advanced or metastatic tyrosine kinase inhibitor (tki)-naïve ros1-positive non-small cell lung cancer (nsclc) (trident-3)
A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of PRTH-101 Alone or in Combination with Pembrolizumab in Adults with Locally Advanced or Metastatic Solid Tumors
An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies
An open-label, multicenter, dose escalation and dose expansion phase 1/2 study with PT217 followed by a key chemotherapy and/or checkpoint inhibitor combination in patients with neuroendocrine carcinomas that are known to be DLL3 expressing cancers
An open-label, multi-center, global, rollover study for patients who have previously been treated with capmatinib (INC280)as monotherapy or in combination in a Novartis Sponsored trial
An Open-label, Multicenter, Phase 1, First in Human, Dose Escalation and Expansion Study of XMT-2056 in Participants with Advanced/Recurrent Solid Tumors that Express HER2
